Adverum Biotechnologies Inc
$ 4.36
0.00%
21 Apr - close price
- Market Cap 96,258,000 USD
- Current Price $ 4.36
- High / Low $ 4.36 / 4.36
- Stock P/E N/A
- Book Value -2.53
- EPS -8.57
- Next Earning Report 2026-05-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.77 %
- ROE -4.18 %
- 52 Week High 5.75
- 52 Week Low 1.78
About
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops candidate gene therapy products to treat eye and rare diseases. The company is headquartered in Redwood City, California.
Analyst Target Price
$4.88
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-12 | 2025-08-11 | 2025-05-07 | 2025-03-17 | 2024-11-07 | 2024-08-12 | 2024-05-09 | 2024-03-18 | 2023-11-09 | 2023-08-10 | 2023-05-11 | 2023-03-30 |
| Reported EPS | -2.03 | -2.34 | -1.9586 | -1.96 | -1.3 | -0.89 | -1.5 | -2.3 | -0.33 | -0.31 | -0.29 | -0.33 |
| Estimated EPS | -1.7 | -2.284 | -1.974 | -1.385 | -1.31 | -1.47 | -1.4 | -3.37 | -0.32 | -0.33 | -0.32 | -0.36 |
| Surprise | -0.33 | -0.056 | 0.0154 | -0.575 | 0.01 | 0.58 | -0.1 | 1.07 | -0.01 | 0.02 | 0.03 | 0.03 |
| Surprise Percentage | -19.4118% | -2.4518% | 0.7801% | -41.5162% | 0.7634% | 39.4558% | -7.1429% | 31.7507% | -3.125% | 6.0606% | 9.375% | 8.3333% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-05 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ADVM
2026-01-14 09:51:00
The global Achromatopsia Market is projected to grow from $121.99 million in 2026 to $191.22 million by 2032, driven by advances in genetic characterization, diagnostics, and therapeutic strategies. The report highlights technological innovations in gene therapy and pharmacological treatments, alongside the impact of US tariff adjustments on the supply chain. Regional insights emphasize varying market dynamics across the Americas, EMEA, and Asia-Pacific.
2026-01-12 15:29:04
Pomerantz LLP is investigating potential securities fraud claims against Adverum Biotechnologies, Inc. (NASDAQ: ADVM) after the company disclosed that its previously issued financial statements for 2022, 2023, and parts of 2024 could no longer be relied upon due to non-cash accounting errors. Following this announcement, Adverum's stock price fell by 12.36%. Investors are encouraged to contact Pomerantz LLP for more information regarding the class action investigation.
2025-12-13 20:09:15
Adverum Biotechnologies (NASDAQ:ADVM) has been downgraded to a "strong sell" by Wall Street Zen, adding to several recent broker downgrades, although MarketBeat's consensus remains a "Hold" with a target price of $10.50. The company recently missed EPS expectations, reporting -$2.03 against an expected -$1.80, and has seen notable insider trading activity. Despite a major shareholder selling over 500,000 shares, the CEO purchased 117,614 shares, and institutional investors collectively own 48.17% of the stock.
2025-12-09 22:09:26
Eli Lilly and Company has successfully completed its tender offer to acquire Adverum Biotechnologies, Inc., with approximately 64% of Adverum’s shares validly tendered. The acquisition, which concluded on December 9, 2025, aims to expand Lilly's gene therapy capabilities, particularly in treating age-related conditions like vision loss. Lilly looks forward to integrating Adverum's expertise to develop innovative genetic medicines.
2025-12-09 22:08:29
Adverum Biotechnologies' CEO, Laurent Fischer, recently purchased shares totaling over $550,000 in two separate transactions in early December. These buys significantly increased his stake in the company. Despite an elevated trading volume and a market capitalization of approximately $96.3 million, the company recently missed its quarterly EPS consensus, and analysts currently have a "Hold" rating on the stock with a $10.50 price target.
2025-12-09 09:29:00
Eli Lilly (LLY) has completed its acquisition of Adverum Biotechnologies (ADVM), gaining the gene therapy candidate Ixo-vec for wet age-related macular degeneration. Lilly is paying $3.56 in cash per Adverum share, plus a contingent value right.
